Efficacy of Huaier granule combined with transcatheter arterial chemoembolization in treatment of primary liver cancer: a meta analysis_CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY

Authors：

ZHANG Shaohua ¹ , TANG Ying ² , YUE Han ¹ , MAO Xingbo ¹ , HUANG Shenqiao ¹ ,  WU Guo ¹ , LI Jingdong ¹

1. The First Department of Hepatobiliary Surgery, Affiliated Hospital of North Sichuan Medical College, Nanchong, Sichuan 637000, P. R. China;
2. Deparment of UItrasonic Diagnosis, Affiliated Hospital of North Sichuan Medical College, Nanchong, Sichuan 637000, P. R. China;

Corresponding author：

WU Guo, Email: xnyywg@126.com

Keywords：

primary liver cancer; Huaier granules; transcatheter arterial chemoembolization; efficacy; safety

DOI：

10.7507/1007-9424.201910035

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

Objective To systematically evaluate efficacy and safety of transcatheter arterial chemoembolization (TACE) combined with Huaier granules in treatment of primary liver cancer (PLC).Methods The databases including the PubMed, Embase, Cochrane Library, Wanfang Data, CNKI, VIP were searched to obtain the relevant literatures of Huaier granule combined with TACE therapy (Huaier+TACE group) and alone TACE therapy (TACE group) in the treatment of PLC. The short-term curative effects (objective response rate and disease control rate), 6 and 12-month survival rates, immune function change, and adverse reactions were extracted. The RevMan 5.3 software was applied to carry out the meta analysis.Results Fifteen studies involving 1 781 cases were enrolled in this study, of which 876 cases underwent the Huaier+TACE, 905 underwent the TACE. The meta analysis results showed that the objective response rate and disease control rate, 6 and 12-month survival rates of the Huaier+TACE group were significantly more superior as compared with of the TACE group (P<0.05), the adverse reaction incidence had no significant difference (P>0.05). Compared with the TACE group, the CD4⁺/CD8⁺ of the Huaier+TACE group was significantly improved (P<0.05).Conclusion From results of meta analysis, Huaier granule combined with TACE could improve therapeutic effect, increase survival rate, and improve life quality of PLC.

Citation： ZHANG Shaohua, TANG Ying, YUE Han, MAO Xingbo, HUANG Shenqiao, WU Guo, LI Jingdong. Efficacy of Huaier granule combined with transcatheter arterial chemoembolization in treatment of primary liver cancer: a meta analysis. CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY, 2020, 27(7): 855-860. doi: 10.7507/1007-9424.201910035 Copy

1.	Pan R, Zhu M, Yu C, et al. Cancer incidence and mortality: A cohort study in China, 2008—2013. Int J Cancer, 2017, 141(7): 1315-1323.
2.	Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin, 2018, 68(6): 394-424.
3.	梁宏元, 卢再鸣. 原发性肝癌综合介入治疗现状与困惑. 临床肝胆病杂志, 2016, 32(1): 44-48.
4.	Chen Q, Shu C, Laurence AD, et al. Effect of Huaier granule on recurrence after curative resection of HCC: a multicentre, randomised clinical trial. Gut, 2018, 67(11): 2006-2016.
5.	Long TT, Liu ZJ, Shang JC, et al. Polygonatum sibiricum polysaccharides play anti-cancer effect through TLR4-MAPK/NF-κB signaling pathways. Int J Biol Macromol, 2018, 111: 813-821.
6.	Li C, Wu X, Zhang HH, et al. A Huaier polysaccharide restrains hepatocellular carcinoma growth and metastasis by suppression angiogenesis. Int J Biol Macromol, 2015, 75: 115-120.
7.	Jadad AR, Moore RA, Carroll D, et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials, 1996, 17(1): 1-12.
8.	郭添胜, 黄福喜, 曹小龙. 槐耳颗粒联合介入治疗原发性肝癌的疗效观察. 实用医学杂志, 2005, 21(16): 1846-1847.
9.	洪政, 王洪涛. 槐耳颗粒联合 TACE 治疗原发性肝癌临床观察. 中华实用中西医杂志, 2006, 19(23): 2841-2843.
10.	阙劲松, 高世洪. 槐耳颗粒联合介入疗法治疗原发性肝癌的疗效观察. 临床和实验医学杂志, 2007, 6(5): 151.
11.	陈文林, 吴海江, 马传学, 等. 介入治疗加槐耳颗粒治疗原发性肝癌的临床观察. 江苏省药学会·第八届江苏省药师周论文集, 2008: 163-164.
12.	王天昌, 蒋明, 崔菲. 槐耳颗粒联合介入治疗原发性肝癌的疗效观察. 中国实用医刊, 2009, 36(14): 79-80.
13.	李馨刚, 许炎. 槐耳颗粒口服联合介入疗法治疗原发性肝癌的细胞免疫变化. 中国民康医学, 2009, 21(18): 2196, 2230.
14.	杜更全, 董志强. 槐耳颗粒联合 TACE 治疗中晚期肝癌的疗效观察. 中国医药指南, 2012, 10(21): 446-447.
15.	汪平, 仲炜, 唐成武, 等. 槐耳颗粒对肝癌栓塞化疗后免疫功能的影响. 中国现代医生, 2013, 51(36): 58-60.
16.	孙学征, 赵振华, 黄志坤, 等. 槐耳颗粒联合 TACE 对中晚期肝癌患者T淋巴细胞亚群的影响. 中国中医药科技, 2013, 20(1): 66.
17.	赵广生, 刘影, 张跃伟, 等. 明胶海绵微粒与洛铂经肝动脉化疗栓塞联合槐耳颗粒治疗原发性肝癌. 中华普通外科杂志, 2013, 28(6): 440-443.
18.	吴晖. 槐耳颗粒联合化疗栓塞术治疗原发性肝癌 96 例. 中国药业, 2014, 23(3): 16-18.
19.	华向东, 尚海, 何忠野, 等. 槐耳颗粒联合经导管肝动脉化疗栓塞在原发性肝癌伴微血管侵犯根治术后的疗效分析. 中国普外基础与临床杂志, 2016, 23(8): 982-986.
20.	蒋蕊. 槐耳颗粒对肝癌栓塞化疗后患者的影响探讨. 临床医药文献电子杂志, 2017, 4(63): 12423, 12425.
21.	董德硕, 刘兆玉. 基于真实世界肝动脉化疗栓塞术联合槐耳颗粒治疗肝细胞癌的临床研究. 现代肿瘤医学, 2018, 26(5): 741-746.
22.	王冠蕾, 富大智, 王本刚. 槐耳颗粒联合吡柔比星介入治疗乙型肝炎肝癌患者的临床疗效. 世界中医药, 2018, 13(7): 1597-1600.
23.	Nie J, Zhao C, Deng LI, et al. Efficacy of traditional Chinese medicine in treating cancer. Biomed Rep, 2016, 4(1): 3-14.
24.	Li C, Wu X, Zhang H, et al. A Huaier polysaccharide inhibits hepatocellular carcinoma growth and metastasis. Tumour Biol, 2015, 36(3): 1739-1745.

1. Pan R, Zhu M, Yu C, et al. Cancer incidence and mortality: A cohort study in China, 2008—2013. Int J Cancer, 2017, 141(7): 1315-1323.
2. Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin, 2018, 68(6): 394-424.
3. 梁宏元, 卢再鸣. 原发性肝癌综合介入治疗现状与困惑. 临床肝胆病杂志, 2016, 32(1): 44-48.
4. Chen Q, Shu C, Laurence AD, et al. Effect of Huaier granule on recurrence after curative resection of HCC: a multicentre, randomised clinical trial. Gut, 2018, 67(11): 2006-2016.
5. Long TT, Liu ZJ, Shang JC, et al. Polygonatum sibiricum polysaccharides play anti-cancer effect through TLR4-MAPK/NF-κB signaling pathways. Int J Biol Macromol, 2018, 111: 813-821.
6. Li C, Wu X, Zhang HH, et al. A Huaier polysaccharide restrains hepatocellular carcinoma growth and metastasis by suppression angiogenesis. Int J Biol Macromol, 2015, 75: 115-120.
7. Jadad AR, Moore RA, Carroll D, et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials, 1996, 17(1): 1-12.
8. 郭添胜, 黄福喜, 曹小龙. 槐耳颗粒联合介入治疗原发性肝癌的疗效观察. 实用医学杂志, 2005, 21(16): 1846-1847.
9. 洪政, 王洪涛. 槐耳颗粒联合 TACE 治疗原发性肝癌临床观察. 中华实用中西医杂志, 2006, 19(23): 2841-2843.
10. 阙劲松, 高世洪. 槐耳颗粒联合介入疗法治疗原发性肝癌的疗效观察. 临床和实验医学杂志, 2007, 6(5): 151.
11. 陈文林, 吴海江, 马传学, 等. 介入治疗加槐耳颗粒治疗原发性肝癌的临床观察. 江苏省药学会·第八届江苏省药师周论文集, 2008: 163-164.
12. 王天昌, 蒋明, 崔菲. 槐耳颗粒联合介入治疗原发性肝癌的疗效观察. 中国实用医刊, 2009, 36(14): 79-80.
13. 李馨刚, 许炎. 槐耳颗粒口服联合介入疗法治疗原发性肝癌的细胞免疫变化. 中国民康医学, 2009, 21(18): 2196, 2230.
14. 杜更全, 董志强. 槐耳颗粒联合 TACE 治疗中晚期肝癌的疗效观察. 中国医药指南, 2012, 10(21): 446-447.
15. 汪平, 仲炜, 唐成武, 等. 槐耳颗粒对肝癌栓塞化疗后免疫功能的影响. 中国现代医生, 2013, 51(36): 58-60.
16. 孙学征, 赵振华, 黄志坤, 等. 槐耳颗粒联合 TACE 对中晚期肝癌患者T淋巴细胞亚群的影响. 中国中医药科技, 2013, 20(1): 66.
17. 赵广生, 刘影, 张跃伟, 等. 明胶海绵微粒与洛铂经肝动脉化疗栓塞联合槐耳颗粒治疗原发性肝癌. 中华普通外科杂志, 2013, 28(6): 440-443.
18. 吴晖. 槐耳颗粒联合化疗栓塞术治疗原发性肝癌 96 例. 中国药业, 2014, 23(3): 16-18.
19. 华向东, 尚海, 何忠野, 等. 槐耳颗粒联合经导管肝动脉化疗栓塞在原发性肝癌伴微血管侵犯根治术后的疗效分析. 中国普外基础与临床杂志, 2016, 23(8): 982-986.
20. 蒋蕊. 槐耳颗粒对肝癌栓塞化疗后患者的影响探讨. 临床医药文献电子杂志, 2017, 4(63): 12423, 12425.
21. 董德硕, 刘兆玉. 基于真实世界肝动脉化疗栓塞术联合槐耳颗粒治疗肝细胞癌的临床研究. 现代肿瘤医学, 2018, 26(5): 741-746.
22. 王冠蕾, 富大智, 王本刚. 槐耳颗粒联合吡柔比星介入治疗乙型肝炎肝癌患者的临床疗效. 世界中医药, 2018, 13(7): 1597-1600.
23. Nie J, Zhao C, Deng LI, et al. Efficacy of traditional Chinese medicine in treating cancer. Biomed Rep, 2016, 4(1): 3-14.
24. Li C, Wu X, Zhang H, et al. A Huaier polysaccharide inhibits hepatocellular carcinoma growth and metastasis. Tumour Biol, 2015, 36(3): 1739-1745.

CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY

Efficacy of Huaier granule combined with transcatheter arterial chemoembolization in treatment of primary liver cancer: a meta analysis

Abstract Full text Figures/Tables Video References Cited by

Previous Article

Next Article

Format

Content